[Federal Register Volume 70, Number 107 (Monday, June 6, 2005)]
[Notices]
[Page 32761]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-11176]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. 2005-P-064]
Grant of Interim Extension of the Term of U.S. Patent No.
4,567,264; Ranolazine
AGENCY: United States Patent and Trademark Office.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for a third one-year interim
extension of the term of U.S. Patent No. 4,567,264.
FOR FURTHER INFORMATION CONTACT: Karin Ferriter by telephone at
(571)272-7744; by mail marked to her attention and addressed to Mail
Stop Patent Ext., Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450; by fax marked to her attention at (571)273-7744; or by
e-mail to [email protected].
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to a year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On March 25, 2005, patent owner Roche Palo Alto LLC, timely filed
an application under 35 U.S.C. 156(d)(5) for a third interim extension
of the term of U.S. Patent No. 4,567,264. The patent claims the active
ingredient ranolazine (RanexaTM). The application indicates,
and the Food and Drug Administration (FDA) has confirmed, that a New
Drug Application for the human drug product ranolazine has been filed
and is currently undergoing regulatory review before the FDA for
permission to market or use the product commercially.
Review of the application indicates that, except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for an additional period of one year
as required by 35 U.S.C. 156(d)(5)(C). Since it is apparent that the
regulatory review period will continue beyond the extended expiration
date of the patent (May 18, 2005), the term of the patent will be
extended under 35 U.S.C. 156(d)(5) for an additional year.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,567,264 is granted for an additional period of one year
from the extended expiration date of the patent, i.e., until May 18,
2006.
Dated: May 26, 2005.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual Property and Director of
the United States Patent and Trademark Office.
[FR Doc. 05-11176 Filed 6-3-05; 8:45 am]
BILLING CODE 3510-16-P